I am a
Home I AM A Search Login

Papers of the Week

2020 May

J Gastroenterol Hepatol



Real-world experience of 12-week DAA regimen of glecaprevir and pibrentasvir in patients with chronic HCV infection.


Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, et al.
J Gastroenterol Hepatol. 2020 May; 35(5):855-861.
PMID: 31609495.


In clinical trials, a pangenotype direct-acting antiviral (DAA) regimen consisting of glecaprevir (GLE) and pibrentasvir (PIB) exhibited high virologic efficacy and tolerability in patients with hepatitis C virus (HCV) infection. This study sought to confirm these findings in real-world settings, focusing on patients with cirrhosis, history of DAA failure, or HCV genotype 3 who were treated with a 12-week regimen, in a large multicenter study from Japan.